Table 1. Patient characteristics.
| Entire Cohort (N = 86) N (%) | Patients without BRCA1 Assessment (N = 45) N (%) | Patients with BRCA1 Assessment (N = 41) N (%) | p | |
| Age, median (range) | 54 (31–79) | 56 (34–74) | 55 (31–79) | 0.78 |
| Menopausal status | 0.51 | |||
| Premenopausal | 36 (42%) | 28 (62.2) | 22 (54%) | |
| Postmenopausal | 50 (58%) | 17 (37.8) | 19 (46%) | |
| Tumor size (cm) | 6 (2.5–12) | 6 (2.50–12) | 6.4 (2.5–12) | 0.34 |
| Tumor differentiation | 0.52 | |||
| Grade I | 8 (10.4) | 5 (13.2) | 3 (7.7) | |
| Grade II | 34 (44.2) | 18 (47.4) | 16 (41) | |
| Grade III | 35 (45.5) | 15 (39.5) | 20 (51.3) | |
| Unknown | 9 | 7 | 2 | |
| Clinical stage | 0.51 | |||
| II | 24 (28%) | 14 (31.1) | 10 (24%) | |
| III | 62 (72%) | 31 (68.9) | 31 (76%) | |
| Pathological response | 0.63 | |||
| Response (G5, G4, G3) | 49 (57%) | 27 (60) | 22 (53.7%) | |
| No response (G2, G1) | 37 (43%) | 18 (40) | 19 (46.3%) | |
| Surgery | 0.54 | |||
| Mastectomy | 78 (91%) | 39 (86.6) | 39 (95%) | |
| Lumpectomy | 8 (9%) | 6 (13.3) | 2 (5%) | |
| Pathological nodal status | 0.29 | |||
| Positive | 69 (80%) | 34 (75.6) | 35 (85%) | |
| Negative | 17 (20%) | 11 (24.4) | 6 (15%) | |
| Histology | 0.41 | |||
| Invasive ductal carcinoma | 79 (92%) | 41 (91.1) | 38 (93%) | |
| Invasive lobular carcinoma | 5 (6%) | 3 (6.7) | 2 (5%) | |
| Other: mucinous, medular | 2 (2%) | 1 (2.2) | 1 (2%) | |
| Estrogen receptor | 0.38 | |||
| 0–4% | 35 (40.7) | 16 (35.6) | 19 (46.3) | |
| 5–100% | 51 (59.3) | 29 (64.4) | 22 (53.7) | |
| Progesterone receptor | 0.65 | |||
| 0–4% | 59 (68.6) | 32 (71.1) | 27 (65.9) | |
| 5–100% | 27 (31.4) | 13 (28.9) | 14 (34.1) | |
| Cytokeratin 5/6 * | 0.60 | |||
| Negative | 66 (78.6) | 35 (81.4) | 31 (75.6) | |
| Positive | 18 (21.4) | 8 (18.6) | 10 (24.4) | |
| HER2 by CISH | 0.99 | |||
| Positive | 17 (20.2) | 9 (20.5) | 8 (20) | |
| Negative | 67 (79.8) | 35 (79.5) | 32 (80) | |
| Vimentin * | 0.56 | |||
| Negative | 72 (84.7) | 37 (82.2) | 35 (87.5) | |
| Positive | 13 (15.3) | 8 (17.8) | 5 (12.5) | |
| Subtypes * | 0.73 | |||
| HER2+/ER- | 11 (13.1) | 5 (11.4) | 6 (15) | |
| Luminal A | 45 (53.6) | 25 (56.8) | 20 (50) | |
| Luminal B | 6 (7.1) | 4 (9.1) | 2 (5) | |
| Basal-like | 22 (26.2) | 10 (22.7) | 12 (30) | |
| BRCA1 (Median, range) | ---- | ---- | 16.68 (2.93–187.40) | ---- |
Clinical characteristics and results of molecular analyses for all 86 patients, for the 41 patients in whom BRCA1 mRNA expression was assessed and for the 45 in whom BRCA1mRNA was not assessed.
*Technical issues made it impossible to assess some patients.